251 related articles for article (PubMed ID: 25008938)
1. Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.
Guayasamin RC; Reynolds TD; Wei X; Fujiwara M; Robek MD
J Virol; 2014 Sep; 88(18):10909-17. PubMed ID: 25008938
[TBL] [Abstract][Full Text] [Related]
2. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
[TBL] [Abstract][Full Text] [Related]
3. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
4. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
5. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
6. Cell Cycle Arrest in G
Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
[TBL] [Abstract][Full Text] [Related]
7. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
Obuchi M; Fernandez M; Barber GN
J Virol; 2003 Aug; 77(16):8843-56. PubMed ID: 12885903
[TBL] [Abstract][Full Text] [Related]
8. Interferon-inducible protein IFI35 negatively regulates RIG-I antiviral signaling and supports vesicular stomatitis virus replication.
Das A; Dinh PX; Panda D; Pattnaik AK
J Virol; 2014 Mar; 88(6):3103-13. PubMed ID: 24371060
[TBL] [Abstract][Full Text] [Related]
9. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
10. Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin.
Smedberg JR; Westcott MM; Ahmed M; Lyles DS
J Virol; 2014 Jan; 88(2):777-85. PubMed ID: 24198430
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.
Wollmann G; Paglino JC; Maloney PR; Ahmadi SA; van den Pol AN
Virology; 2015 Jan; 475():1-14. PubMed ID: 25462341
[TBL] [Abstract][Full Text] [Related]
12. mRNA cap methylation influences pathogenesis of vesicular stomatitis virus in vivo.
Ma Y; Wei Y; Zhang X; Zhang Y; Cai H; Zhu Y; Shilo K; Oglesbee M; Krakowka S; Whelan SP; Li J
J Virol; 2014 Mar; 88(5):2913-26. PubMed ID: 24371058
[TBL] [Abstract][Full Text] [Related]
13. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
[TBL] [Abstract][Full Text] [Related]
14. [Vesicular stomatitis virus (VSV) as a vaccine vector for immunization against viral infections].
Tomczyk T; Orzechowska B
Postepy Hig Med Dosw (Online); 2013 Jan; 67():1345-58. PubMed ID: 24379275
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
Shinozaki K; Ebert O; Suriawinata A; Thung SN; Woo SL
J Virol; 2005 Nov; 79(21):13705-13. PubMed ID: 16227290
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969
[TBL] [Abstract][Full Text] [Related]
17. The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.
Cobleigh MA; Bradfield C; Liu Y; Mehta A; Robek MD
J Virol; 2012 Apr; 86(8):4253-61. PubMed ID: 22345454
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
19. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
20. Concomitant TLR/RLH signaling of radioresistant and radiosensitive cells is essential for protection against vesicular stomatitis virus infection.
Spanier J; Lienenklaus S; Paijo J; Kessler A; Borst K; Heindorf S; Baker DP; Kröger A; Weiss S; Detje CN; Staeheli P; Kalinke U
J Immunol; 2014 Sep; 193(6):3045-54. PubMed ID: 25127863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
